MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: adam hefian who wrote (658)	2/12/1998 8:02:00 PM
From: Glenn W	of 1826

>MOGN could not penetrate $5,that definitely is a bad sign.MGI 114 >Partner is no where in sight,highly unlikely that there will be >one.Approval on Syjogren looks like 50/50.Phase 2 might never >happen.All in all we could be heading down to $1 soon.Reminds me >of a similar situation-------CHAI I agree that MOGN seems to have a resistance point at $5, and I alos have no idea where an MGI 114 partner is, but where did you get the information that FDA approval of Salagen for Sjogren's is a 50/50 proposition? Do you have some information on where the FDA is leaning? I have heard nothing. Also, my understanding is that Blitzer was pretty positive about the prospects of going into Phase II with MGI 114. Do you have information about this as well? Please help me out! Glenn

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next